Aberrant type 1 immunity drives susceptibility to mucosal fungal infections

doi:10.1126/science.aay5731

. 2021 Jan 15;371(6526):eaay5731.

doi: 10.1126/science.aay5731.

Aberrant type 1 immunity drives susceptibility to mucosal fungal infections

Timothy J Break^#¹, Vasileios Oikonomou^#¹, Nicolas Dutzan², Jigar V Desai¹, Marc Swidergall^{3

4}, Tilo Freiwald⁵, Daniel Chauss⁵, Oliver J Harrison⁶, Julie Alejo⁷, Drake W Williams², Stefania Pittaluga⁷, Chyi-Chia R Lee⁷, Nicolas Bouladoux⁶, Muthulekha Swamydas¹, Kevin W Hoffman⁸, Teresa Greenwell-Wild², Vincent M Bruno⁹, Lindsey B Rosen¹⁰, Wint Lwin¹¹, Andy Renteria¹, Sergio M Pontejo¹², John P Shannon¹³, Ian A Myles¹⁴, Peter Olbrich¹⁰, Elise M N Ferré¹, Monica Schmitt¹, Daniel Martin¹⁵; Genomics and Computational Biology Core; Daniel L Barber¹⁶, Norma V Solis³, Luigi D Notarangelo¹⁷, David V Serreze¹⁸, Mitsuru Matsumoto¹⁹, Heather D Hickman¹³, Philip M Murphy¹², Mark S Anderson¹¹, Jean K Lim⁸, Steven M Holland¹⁰, Scott G Filler^{3

4}, Behdad Afzali⁵, Yasmine Belkaid⁶, Niki M Moutsopoulos², Michail S Lionakis²⁰

Affiliations

¹ Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA.
² Oral Immunity and Inflammation Section, National Institute of Dental and Craniofacial Research (NIDCR), Bethesda, MD, USA.
³ Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
⁴ David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
⁵ Immunoregulation Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD, USA.
⁶ Metaorganism Immunity Section, Laboratory of Immune System Biology, NIAID, Bethesda, MD, USA.
⁷ Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, MD, USA.
⁸ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁹ Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
¹⁰ Immunopathogenesis Section, LCIM, NIAID, Bethesda, MD, USA.
¹¹ Diabetes Center, University of California, San Francisco, CA, USA.
¹² Molecular Signaling Section, Laboratory of Molecular Immunology, NIAID, Bethesda, MD, USA.
¹³ Viral Immunity and Pathogenesis Unit, LCIM, NIAID, Bethesda, MD, USA.
¹⁴ Epithelial Therapeutics Unit, LCIM, NIAID, Bethesda, MD, USA.
¹⁵ Genomics and Computational Biology Core, NIDCR, Bethesda, MD, USA.
¹⁶ T Lymphocyte Biology Section, Laboratory of Parasitic Diseases, NIAID, Bethesda, MD, USA.
¹⁷ Immune Deficiency Genetics Section, LCIM, NIAID, Bethesda, MD, USA.
¹⁸ Jackson Laboratory, Bar Harbor, ME, USA.
¹⁹ Division of Molecular Immunology, Institute for Enzyme Research, Tokushima University, Tokushima, Japan.
²⁰ Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA. lionakism@mail.nih.gov.

^# Contributed equally.

PMID: 33446526
PMCID: PMC8326743
DOI: 10.1126/science.aay5731

Aberrant type 1 immunity drives susceptibility to mucosal fungal infections

Timothy J Break et al. Science. 2021.

. 2021 Jan 15;371(6526):eaay5731.

doi: 10.1126/science.aay5731.

Authors

Affiliations

¹ Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA.
² Oral Immunity and Inflammation Section, National Institute of Dental and Craniofacial Research (NIDCR), Bethesda, MD, USA.
³ Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
⁴ David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
⁵ Immunoregulation Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD, USA.
⁶ Metaorganism Immunity Section, Laboratory of Immune System Biology, NIAID, Bethesda, MD, USA.
⁷ Laboratory of Pathology, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, MD, USA.
⁸ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁹ Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
¹⁰ Immunopathogenesis Section, LCIM, NIAID, Bethesda, MD, USA.
¹¹ Diabetes Center, University of California, San Francisco, CA, USA.
¹² Molecular Signaling Section, Laboratory of Molecular Immunology, NIAID, Bethesda, MD, USA.
¹³ Viral Immunity and Pathogenesis Unit, LCIM, NIAID, Bethesda, MD, USA.
¹⁴ Epithelial Therapeutics Unit, LCIM, NIAID, Bethesda, MD, USA.
¹⁵ Genomics and Computational Biology Core, NIDCR, Bethesda, MD, USA.
¹⁶ T Lymphocyte Biology Section, Laboratory of Parasitic Diseases, NIAID, Bethesda, MD, USA.
¹⁷ Immune Deficiency Genetics Section, LCIM, NIAID, Bethesda, MD, USA.
¹⁸ Jackson Laboratory, Bar Harbor, ME, USA.
¹⁹ Division of Molecular Immunology, Institute for Enzyme Research, Tokushima University, Tokushima, Japan.
²⁰ Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology (LCIM), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA. lionakism@mail.nih.gov.

^# Contributed equally.

PMID: 33446526
PMCID: PMC8326743
DOI: 10.1126/science.aay5731

Abstract

Human monogenic disorders have revealed the critical contribution of type 17 responses in mucosal fungal surveillance. We unexpectedly found that in certain settings, enhanced type 1 immunity rather than defective type 17 responses can promote mucosal fungal infection susceptibility. Notably, in mice and humans with AIRE deficiency, an autoimmune disease characterized by selective susceptibility to mucosal but not systemic fungal infection, mucosal type 17 responses are intact while type 1 responses are exacerbated. These responses promote aberrant interferon-γ (IFN-γ)- and signal transducer and activator of transcription 1 (STAT1)-dependent epithelial barrier defects as well as mucosal fungal infection susceptibility. Concordantly, genetic and pharmacologic inhibition of IFN-γ or Janus kinase (JAK)-STAT signaling ameliorates mucosal fungal disease. Thus, we identify aberrant T cell-dependent, type 1 mucosal inflammation as a critical tissue-specific pathogenic mechanism that promotes mucosal fungal infection susceptibility in mice and humans.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Figures

**Fig. 1.. *Aire* deficiency causes mucosal fungalspecific infection susceptibility without a defect in mucosal IL-17R/IL-22–dependent immune responses.**
(A) Progression of fungal burden in wild-type and *Aire^−/−* tongue tissue after oral *C. albicans* infection (N = 9 to 16 per group; three experiments). (B) Representative histological micrographs of periodic acid-Schiff staining in wild-type and *Aire^−/−* tongue tissue at day 5 after infection. Scale bars, 100 μm (N = 8 per group; two experiments). (C) Fungal burden in wild-type and *Aire^−/−* kidney tissue at day 4 after intravenous *C. albicans* challenge (N = 6 to 8 per group; two experiments). (D to F) Frequencies of indicated lymphoid cells with (D) IL-17A–, (E) IL-17F–, and (F) IL-22–producing potential in wild-type and *Aire^−/−* oral gingival mucosal tissue at day 1 after infection (N = 5 to 13 per group; two to six experiments). ILCs, innate lymphoid cells. (G to I) Concentrations of IL-17A (G), IL-17F (H), and IL-22 (I) in wild-type and *Aire^−/−* tongue tissue homogenates before and after infection (N = 6 to 10 per group; two to three experiments). (J to M) Relative mRNA expression of *S100a8* (J), *S100a9* (K), *Defb3* (L), and *Defb1* (M) in wild-type and *Aire^−/−* tongue tissue before and after infection (N = 4 to 9 per group; two experiments). (N) Protein concentration of Ccl20 in wild-type and *Aire^−/−* tongue tissue homogenates before and after infection (N = 6 to 10 per group; two experiments). (O) Saliva was harvested after pilocarpine administration in wild-type and *Aire^−/−* mice over 20 min. The percentage of *C. albicans* that remained alive relative to the input inoculum after 1 hour or 3 hours of incubation ex vivo with salivary secretions harvested from wild-type and *Aire^−/−* mice was calculated (N = 6 to 9 per group; two experiments). (P) The tongues of wild-type and *Aire^−/−* mice were harvested at day 1 after infection. Epithelial cells were isolated by FACS. mRNA was extracted and RNA-seq was then performed. The heat map shows expression of selected IL-17R–regulated genes curated by Ingenuity Pathway Analysis (IPA) in RNA-seq of oral epithelial cells of *Aire^+/+* (N = 3) and *Aire^−/−* (N = 3) mice with oral candidiasis. (Q and R) Fungal burden in *Aire^−/−* tongue tissue at day 4 after infection following antibody-mediated depletion of IL-17A and IL-17F (Q) or IL-22 (R) relative to control antibody (N = 5 to 7 per group; two experiments). All quantitative data are means ± SEM. *P < 0.05, **P < 0.01, ****P < 0.0001 as calculated using unpaired t test [(A), day 1, (O), and (Q)] or Mann-Whitney U test [(A), days 3 and 5, (C), (N), and (R)]; ns, not significant.

**Fig. 2.. APECED patients have intact mucosal type 17 immune responses.**
(A) Frequencies of indicated lymphoid cells with IL-17A–producing potential in healthy donor (N = 8) or APECED patient (N = 3) oral gingival mucosal tissue. Each dot represents an individual patient. ILCs, innate lymphoid cells. No IL-17A production by CD8⁺ T cells was observed in any of the healthy donors or APECED patients. (B and C) Relative mRNA expression of *IL17A, IL17F*, and *IL22* (B) and *S100A9* (C) in healthy donor (N = 3) and APECED patient (N = 6) oral gingival mucosal tissue. (D) S100A8 and S100A9 concentrations in saliva of healthy donors (N = 33 to 38) and APECED patients (N = 75 to 77). (E) Oral gingival mucosal tissue was obtained from uninfected healthy donors (HD; N = 4) and uninfected APECED patients (N = 5), mRNA was extracted, and RNA-seq was performed. The heat map shows expression of IL-17R–regulated genes, curated from an earlier study (19), in RNA-seq of oral gingival mucosal tissue from APECED patients versus healthy donors. All quantitative data are means ± SEM.

**Fig. 3.. Pathogenic TCRαβ⁺ cells drive mucosal fungal infection susceptibility in *Aire* deficiency.**
(A and B) Numbers of CD4⁺ (A) and CD8⁺ (B) T cells in wild-type and *Aire^−/−* tonguetissue before and after oral *C. albicans* infection (N = 6 to 10 per group; two experiments). (C and D) Representative contour plots of CD44 and CD69 expression (left, day 0) and proportions of CD44^hiCD69⁺ cells (right, days 0 and 1) within CD4⁺ (C) and CD8⁺ (D) T cells in wild-type and *Aire^−/−* tongue tissue (N = 6 to 10 per group; two experiments). (E and F) Representative immunofluorescence images of CD4 and CD8 staining [(E), top and bottom, respectively] and quantification of CD4⁺ and CD8⁺ T cells (F) within epithelial and submucosal layers of wild-type and *Aire^−/−* tongue tissue at day 1 after infection. Scale bars, 100 μm (N = 6 or 7 per group; two experiments). (G) Immunohistochemical analysis of CD4 (brown) and CD8 (red) in healthy donor and APECED patient oral gingival mucosal tissue. Scale bars, 1200 μm (top), 200 μm (bottom). Shown are images from one of two examined healthy donors and one of three examined APECED patients; images from all patients are shown in fig. S15. (H and I) *Aire^−/−Tcra^−/−* mice control mucosal fungal infection better than do *Aire^−/−* mice, as indicated by fungal burden analysis in tongue tissue (H) and representative histological micrographs of periodic acid-Schiff staining in wild-type, *Aire^−/−*, and *Aire^−/−Tcra^−/−* tongue tissue at day 5 after infection (I). Scale bars, 200 μm (N = 6 to 16 per group; three experiments). (J and K) In *Aire^−/−* mice, antibody-mediated depletion of CD4⁺ T cells [(J); N = 8 or 9 per group, three experiments] or CD8⁺ T cells [(K); N = 4 to 6 per group, two experiments] results in decreased fungal burden in tongue tissue. (L) Fungal burden in tongue tissue of *Tcra^−/−* recipient mice 10 weeks after adoptive transfer of the indicated T cells derived from wild-type or *Aire^−/−* mice (N = 6 to 10 per group; three experiments). All quantitative data are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as calculated using unpaired t test [(A), days 1 and 3, (B), days 0 and 5, (C), day 0, and (D)], Mann-Whitney U test [(A), days 0 and 5, (B), days 1 and 3, (C), day 1, (F), (J), and (K)], one-way ANOVA with Holm-Šidák multiple-comparisons test (H), or Kruskal-Wallis H test with Dunn’s multiple-comparisons test (L).

**Fig. 4.. *Aire* deficiency results in IFN-γ–driven mucosal interferonopathy.**
(A and B) Relative mRNA expression of *Ifng* [(A); N = 4 to 9 per group; two experiments] and concentration of IFN-γ [(B); N = 5 to 20 per group; two experiments] in wild-type and *Aire^−/−* tongue tissue before and after infection. (C and D) Representative contour plots of IFN-γ expression (left; day 0) and frequencies of IFN-γ–producing cells (right; days 0 and 1) within CD4⁺ (C) and CD8⁺ (D) T cells in wild-type and *Aire^−/−* oral gingival mucosal tissue (N = 4 to 8 per group; two experiments). (E) Relative mRNA expression of *Stat1* in wild-type and *Aire^−/−* tongue tissue homogenates before and after infection (N = 4 to 13 per group; two experiments). (F and G) Concentrations of IFN-γ–inducible CXCL9 (F) and CXCL10 (G) in wild-type and *Aire^−/−* tongue tissue homogenates before and after infection (N = 6 to 10 per group; two to three experiments). (H) Epithelial layers of wild-type, *Aire^−/−*, and *Aire^−/−Ifng^−/−* tongue tissues were harvested at day 1 after infection for immunoblot analysis of phospho-Stat1 (Tyr⁷⁰¹), total Stat1, and β-actin as loading control. Top, quantification of protein immunoblot data; bottom, representative protein immunoblot images (N = 8 to 10 per group; three experiments). (I to K) Tongues of wild-type and *Aire^−/−* mice were harvested at day 1 after infection. Epithelial cells were isolated by FACS. mRNA was extracted and RNA-seq was then performed. (I) Principal components analysis of RNA-seq in wild-type (N = 3) and *Aire^−/−* (N = 3) oral epithelial cells at day 1 after infection. (J) Pathway analysis using differentially expressed genes between wild-type and *Aire^−/−* oral epithelial cells was performed using Enrichr and graphed according to enrichment score for significant Reactome biological processes. (K) Volcano plot of RNA-seq demonstrating differential gene expression in wild-type and *Aire^−/−* oral epithelial cells at day 1 after infection. Shown are IFN-γ–dependent genes. Each dot represents an individual mouse. All quantitative data are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as calculated using unpaired t test [(A), (C), (D), day 0, and (G), day 0], unpaired t test with Welch’s correction [(B), day 3, and (E), days 0, 3, and 5], Mann-Whitney U test [(B), days 0, 1, and 5, (D), day 1, (E), day 1, (F), and (G), days 1, 3, and 5] or one-way ANOVA with Holm-Šidák multiple-comparisons test (H).

**Fig. 5.. APECED patients exhibit IFN-γ/STAT1–associated mucosal interferonopathy.**
(A and B) Representative contour plots of IFN-γ expression within CD4⁺ (A) and CD8⁺ (B) T cells in healthy donor and APECED patient oral gingival mucosal tissue. (C and D) Frequencies of CD4⁺ (C) and CD8⁺ (D) T cells with IFN-γ–producing potential in healthy donor (N = 8) or APECED patient (N = 3) oral gingival mucosal tissue. (E and F) Concentrations of IFN-γ–inducible CXCL9 (E) and CXCL10 (F) in saliva of healthy donors (N = 28 to 31) and APECED patients (N = 73 to 79). (G) Immunohistochemical analysis of phospho-STAT1 in healthy donor and APECED patient oral gingival mucosal tissue. Scale bars, 400 μm. (H to K) Oral gingival mucosal tissue was obtained from uninfected healthy donors (N = 4) and uninfected APECED patients (N = 5), mRNA was extracted, and RNA-seq was performed. (H) Volcano plot comparing RNA-seq of oral gingival mucosal tissue from APECED patients (N = 5) versus healthy donors (HD; N = 4). Highlighted in red are differentially expressed genes [DEGs; fold change (FC) ≥ ±2 at FDR < 0.05]. Marked are select IFN-γ–regulated genes. (I) Top five enriched MSigDB hallmark gene sets in DEGs from (H). Shown are −log₁₀ FDR q-value (bottom) and fold enrichment (FE; top). (J) Heat map showing expression of the 11 enriched IFN-γ response genes from (I) in each sample. (K) Ingenuity Pathway Analysis (IPA)–predicted upstream regulators of DEGs in humans (APECED patients versus HD) and mice (*Aire^−/−* versus *Aire^+/+*). The heat map shows activation Z-scores of the top five predicted cytokines or transcription factors. All quantitative data are means ± SEM. **P < 0.01, ****P < 0.0001 as calculated using unpaired t test [(C) and (D)] or Mann-Whitney U test [(E) and (F)].

**Fig. 6.. Excessive IFN-γ in *Aire*-deficient mice drives oral epithelial barrier defects.**
(A to E) Oral epithelial cells from tongue tissue of *Aire^−/−* mice exhibit decreased survival relative to wild-type and *Aire^−/−Ifng^−/−* mice. (A) Representative contour plots of dead cell dye–positive oral epithelial cells; (B) frequencies of dead cell dye–positive oral epithelial cells; (C) numbers of live oral epithelial cells at day 1 after infection (N = 6 to 8 per group, two experiments); representative images (D) and frequencies (E) of propidium iodide (PI)–positive oral epithelial cells from wild-type, *Aire^−/−*, and *Aire^−/−Ifng^−/−* mice as assessed by two-photon confocal imaging at day 1 after infection. Scale bars, 50 μm (N = 17 to 25 per group, three experiments). (F and G) Epithelial layers of wild-type, *Aire^−/−*, and *Aire^−/−Ifng^−/−* tongue tissues were harvested at day 1 after infection for immunoblot analyses. Shown are quantification of protein immunoblot data and representative protein immunoblot images of γ-H2A.X (phosphorylated Ser¹³⁹) [(F); N = 10 or 11 per group, three experiments] and Ki-67 [(G); N = 12 to 15 per group, three experiments]. β-Actin or α/β-tubulin were used as loading controls. (H and I) Immunohistochemical analysis of Ki-67 in the oral epithelium of tongue tissue of wild-type, *Aire^−/−*, and *Aire^−/−Ifng^−/−* mice at day 1 after infection. (H) Summary histology score data; (I) representative immunohistochemistry images. Scale bars, 150 μm (N = 7 to 13 per group, three experiments). (J) Increased oral mucosal barrier permeability in *Aire^−/−* mice, as shown by quantification of the amount of FITC-dextran measured in the serum of wild-type, *Aire^−/−*, and *Aire^−/−Ifng^−/−* mice at day 1 after infection following topical application of FITC-dextran onto the mouse tongue (N = 10 or 11 per group, three experiments). The dotted horizontal line indicates the fluorescence values obtained in the serum of mice in which FITC-dextran was not applied onto the mouse tongue. (K) Epithelial layers of wild-type, *Aire^−/−*, and *Aire^−/−Ifng^−/−* tongue tissues were harvested at day 1 after infection for immunoblot analyses. Left, quantification of protein immunoblot data; right, representative protein immunoblot images of claudin-1 with β-actin as loading control (N = 14 to 18 per group, four experiments). Each dot represents an individual mouse or an individual field of view of mouse tongue tissue imaged using two-photon confocal microscopy (E). All quantitative data are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as calculated using one-way ANOVA with Newman-Keuls multiple comparisons test [(C) and (G)], one-way ANOVA with Holm-Šidák multiple comparisons test [(B), (E), (F), (H), and (J)], or Kruskal-Wallis H test with Dunn’s multiple-comparisons test (K).

**Fig. 7.. Prolonged IFN-γ exposure impairs the viability and barrier integrity of human oral epithelial cells.**
OKF6/TERT-2 human oral epithelial cells were exposed for 72 hours to the indicated concentrations of IFN-γ (U, units). (A) Lactate dehydrogenase (LDH) release was assessed after changing the culture media, 8 hours after *C. albicans* infection, with a starting point of similar confluency (N = 8 or 9 per group; three experiments). (B) Permeability of confluent cells assessed by measuring fluorescent counts of FITC-dextran in receiver wells (N = 6 to 9 per group; three experiments). (C) Quantification of protein immunoblot data (top) and representative protein immunoblot images (bottom) of claudin-1 with GAPDH as loading control (N = 3 per group; three experiments). (D) Representative images of claudin-1 expression and localization in human oral epithelial cells. Scale bar, 20 mm. Shown are mean (±SEM) fluorescent values of claudin-1 obtained from three randomly selected high-power fields per experiment (three independent experiments). All quantitative data are means ± SEM. ***P < 0.001, ****P < 0.0001 as calculated using one-way ANOVA with Dunnett’s post hoc multiple-comparisons test.

**Fig. 8.. Inhibition of IFN-γ or JAK-STAT signaling in Aire-deficient mice ameliorates mucosal fungal infection susceptibility.**
(A) Fungal burden in *Aire^−/−* and *Aire^−/−Ifng^−/−* tongue tissue after oral *C. albicans* infection (N = 9 or 10 per group; three experiments). (B) Representative histological micrographs of periodic acid-Schiff staining in *Aire^−/−* and *Aire^−/−Ifng^−/−* tongue tissue at day 5 after infection. Scale bars, 150 μm (N = 5 or 6 per group; two experiments). (C) Fungal burden in tongue tissue of *Tcra^−/−* recipient mice 10 weeks after adoptive transfer of the indicated T cells derived from wild-type, *Aire^−/−*, or *Aire^−/−Ifng^−/−* mice (N = 7 to 14 per group; five experiments). (D and E) Fungal burden in tongue tissue of *Aire^−/−* mice at day 5 after infection following (D) antibody-mediated neutralization of IFN-γ (N = 6 per group; two experiments) or (E) ruxolitinib administration (N = 9 to 11 per group; three experiments). All quantitative data are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 as calculated using Mann-Whitney U test [(A), (D), and (E)] or Kruskal-Wallis H test with Dunn’s multiple-comparisons test (C).

See this image and copyright information in PMC

Comment in

Comment on "Aberrant type 1 immunity drives susceptibility to mucosal fungal infections".
Puel A, Casanova JL. Puel A, et al. Science. 2021 Sep 17;373(6561):eabi5459. doi: 10.1126/science.abi5459. Epub 2021 Sep 16. Science. 2021. PMID: 34529464 Free PMC article.
Comment on "Aberrant type 1 immunity drives susceptibility to mucosal fungal infections".
Kisand K, Meager A, Hayday A, Willcox N. Kisand K, et al. Science. 2021 Sep 17;373(6561):eabi6235. doi: 10.1126/science.abi6235. Epub 2021 Sep 16. Science. 2021. PMID: 34529474

Cited by

Single-cell RNA sequencing highlights the immunosuppression of IDO1⁺ macrophages in the malignant transformation of oral leukoplakia.
Zhang Y, Zhang J, Zhao S, Xu Y, Huang Y, Liu S, Su P, Wang C, Li Y, Li H, Yang P, Yang C. Zhang Y, et al. Theranostics. 2024 Aug 12;14(12):4787-4805. doi: 10.7150/thno.99112. eCollection 2024. Theranostics. 2024. PMID: 39239507 Free PMC article.
Retrospective identification of the first cord blood-transplanted severe aplastic anemia in a STAT1-associated chronic mucocutaneous candidiasis family: case report, review of literature and pathophysiologic background.
Fink FM, Höpfl R, Witsch-Baumgartner M, Kropshofer G, Martin S, Fink V, Heeg M, Peters C, Zschocke J, Haas OA. Fink FM, et al. Front Immunol. 2024 Jul 24;15:1430938. doi: 10.3389/fimmu.2024.1430938. eCollection 2024. Front Immunol. 2024. PMID: 39114664 Free PMC article. Review.
Clinical Mycology Today: Emerging Challenges and Opportunities.
Little J, Rauseo AM, Zuniga-Moya JC, Spec A, Pappas P, Perfect J, McCarthy T, Schwartz IS. Little J, et al. Open Forum Infect Dis. 2024 Jun 27;11(7):ofae363. doi: 10.1093/ofid/ofae363. eCollection 2024 Jul. Open Forum Infect Dis. 2024. PMID: 39045011 Free PMC article. Review.
Epithelial responses to fungal pathogens.
Mills KAM, Aufiero MA, Hohl TM. Mills KAM, et al. Curr Opin Microbiol. 2024 Aug;80:102508. doi: 10.1016/j.mib.2024.102508. Epub 2024 Jul 10. Curr Opin Microbiol. 2024. PMID: 38986398 Review.
The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
Oikonomou V, Smith G, Constantine GM, Schmitt MM, Ferré EMN, Alejo JC, Riley D, Kumar D, Dos Santos Dias L, Pechacek J, Hadjiyannis Y, Webb T, Seifert BA, Ghosh R, Walkiewicz M, Martin D, Besnard M, Snarr BD, Deljookorani S, Lee CR, DiMaggio T, Barber P, Rosen LB, Cheng A, Rastegar A, de Jesus AA, Stoddard J, Kuehn HS, Break TJ, Kong HH, Castelo-Soccio L, Colton B, Warner BM, Kleiner DE, Quezado MM, Davis JL, Fennelly KP, Olivier KN, Rosenzweig SD, Suffredini AF, Anderson MS, Swidergall M, Guillonneau C, Notarangelo LD, Goldbach-Mansky R, Neth O, Monserrat-Garcia MT, Valverde-Fernandez J, Lucena JM, Gomez-Gila AL, Garcia Rojas A, Seppänen MRJ, Lohi J, Hero M, Laakso S, Klemetti P, Lundberg V, Ekwall O, Olbrich P, Winer KK, Afzali B, Moutsopoulos NM, Holland SM, Heller T, Pittaluga S, Lionakis MS. Oikonomou V, et al. N Engl J Med. 2024 May 30;390(20):1873-1884. doi: 10.1056/NEJMoa2312665. N Engl J Med. 2024. PMID: 38810185

See all "Cited by" articles

References

1. Puel A et al., Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332, 65–68 (2011). doi: 10.1126/science.1200439; - DOI - PMC - PubMed
1. Lévy R et al., Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency. Proc. Natl. Acad. Sci. U.S.A 113, E8277–E8285 (2016). doi: 10.1073/pnas.1618300114; - DOI - PMC - PubMed
1. Boisson B et al., An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity 39, 676–686 (2013). doi: 10.1016/j.immuni.2013.09.002; - DOI - PMC - PubMed
1. Ling Y et al., Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J. Exp. Med. 212, 619–631 (2015). doi: 10.1084/jem.20141065; - DOI - PMC - PubMed
1. Lionakis MS, Levitz SM, Host Control of Fungal Infections: Lessons from Basic Studies and Human Cohorts. Annu. Rev. Immunol. 36, 157–191 (2018). doi: 10.1146/annurev-immunol-042617-053318; - DOI - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- H1 Connect
- scite Smart Citations
Molecular Biology Databases
- Mouse Genome Informatics (MGI)
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

[1] Puel A et al., Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332, 65–68 (2011). doi: 10.1126/science.1200439; - DOI - PMC - PubMed

[2] Puel A et al., Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332, 65–68 (2011). doi: 10.1126/science.1200439; - DOI - PMC - PubMed

[3] Lévy R et al., Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency. Proc. Natl. Acad. Sci. U.S.A 113, E8277–E8285 (2016). doi: 10.1073/pnas.1618300114; - DOI - PMC - PubMed

[4] Lévy R et al., Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency. Proc. Natl. Acad. Sci. U.S.A 113, E8277–E8285 (2016). doi: 10.1073/pnas.1618300114; - DOI - PMC - PubMed

[5] Boisson B et al., An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity 39, 676–686 (2013). doi: 10.1016/j.immuni.2013.09.002; - DOI - PMC - PubMed

[6] Boisson B et al., An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity 39, 676–686 (2013). doi: 10.1016/j.immuni.2013.09.002; - DOI - PMC - PubMed

[7] Ling Y et al., Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J. Exp. Med. 212, 619–631 (2015). doi: 10.1084/jem.20141065; - DOI - PMC - PubMed

[8] Ling Y et al., Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J. Exp. Med. 212, 619–631 (2015). doi: 10.1084/jem.20141065; - DOI - PMC - PubMed

[9] Lionakis MS, Levitz SM, Host Control of Fungal Infections: Lessons from Basic Studies and Human Cohorts. Annu. Rev. Immunol. 36, 157–191 (2018). doi: 10.1146/annurev-immunol-042617-053318; - DOI - PubMed

[10] Lionakis MS, Levitz SM, Host Control of Fungal Infections: Lessons from Basic Studies and Human Cohorts. Annu. Rev. Immunol. 36, 157–191 (2018). doi: 10.1146/annurev-immunol-042617-053318; - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Aberrant type 1 immunity drives susceptibility to mucosal fungal infections

Affiliations

Aberrant type 1 immunity drives susceptibility to mucosal fungal infections

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases

Research Materials

Miscellaneous

Abstract

Conflict of interest statement

Figures

Comment in

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases

Research Materials

Miscellaneous